InterMune Inc (NASDAQ:ITMN)
| 9.83 Data as of Jun 17 |  +0.12 / +1.24%Today’s Change | 7.21 Today|||52-Week Range 12.77 | +1.44% Year-to-Date |
Latest ITMN News | Press Releases
Today’s Trading
| Previous close | 9.71 |
| Today’s open | 9.75 |
| Day’s range | 9.72 - 10.00 |
| Volume | 1,063,863 |
| Average volume (3 months) | 1,286,037 |
| Market cap | $802.3M |
| Dividend yield | -- |
Data as of 3:59pm ET, 06/17/2013
Growth & Valuation
| Earnings growth (last year) | +10.85% |
| Earnings growth (this year) | -20.54% |
| Earnings growth (next 5 years) | +60.00% |
| Revenue growth (last year) | +2.12% |
| P/E ratio | NM |
| Price/Sales | 24.13 |
| Price/Book | 9.79 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| SZYMSolazyme Inc | -0.06 | -0.51% |
| MNTAMomenta Pharmaceutic... | -0.26 | -1.85% |
| HALOHalozyme Therapeutic... | -0.21 | -3.27% |
| PLXProtalix Biotherapeu... | +0.06 | +1.20% |
Data as of 4:01pm ET, 06/17/2013
Financials
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | -$0.70 |
| Annual revenue (last year) | $26.2M |
| Annual profit (last year) | -$150.1M |
| Net profit margin | -705.62% |
Profile
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Daniel G. Welch, MBA |
Executive VP, Chief Financial & Accounting Officer John C. Hodgman, MBA |
Corporate headquarters Brisbane, California |
Forecasts
